Skip to main content

Plant Foods and Dietary Supplements: Building Solid Foundations for Clinical Trials

Cover image for Research Topic "Plant Foods and Dietary Supplements: Building Solid Foundations for Clinical Trials"
130kviews
Editorial11 April 2022
Editorial: Plant Foods and Dietary Supplements: Building Solid Foundations for Clinical Trials

Yields of clear, evidence-based public health guidance have been similarly sparse for research on many other natural products (NP). With the goal of facilitating the development of such guidance by increasing the application of good practices to the foundational research, this topic expands on a 2019 review (1). The papers in this collection delve deeper into ways to increase the replicability, and thus also the public health-relevant yields from NP research across the spectrum from chemical characterization to clinical trials.Increased clarity on which components within a chemically complex NP participate in modulating specific biological outcomes should increase the information gained from clinical trials of these products. A related question is "how much of each key chemical reaches the in vivo site of action?" Aspects of this include product stability and replicability, bioavailability and metabolism. Optimization of methods for biochemical characterization and standardization of chemically complex NP are described in this topic by Abraham and Kellogg, Coskun et al., Floyd et al., and Lyu et Floyd et al., Weaver and Hodges and Wright et al. note the challenge and importance of evaluating absorption and pharmacokinetics for chemically complex products. Heterogeneity -genetic, epigenetic, dietary, etc, among humans, as well as between species -may alter product metabolic rates and the formation of biologically active metabolites(2). Chilton et al demonstrate the application of several approaches to detect human genetic variants which critically modify metabolic flux and the health effects of food (or other NP), with implications for optimizing clinical trial inclusionary criteria and interpretations.Floyd et al. describe the challenges of designing pre-clinical studies appropriately for translation to human studies. They highlight the importance of selecting the optimal animal models and dosing regimens for the outcomes of interest and for relevance to the population(s) of interest, and note the importance of considering potential sex differences. Weaver and Hodges note that while stringent inclusionary criteria may decrease the sample size required to provide a reasonable likelihood of avoiding a false positive or false negative result, greater inclusivity may allow greater generalizability. Floyd et al. add that other factors such as circadian rhythm and diet should be documented if not controlled, since they may strongly modulate pharmacokinetics.Moving further towards translation, issues of safety, optimal dosing regimen, tolerability, ability to mask the intervention in controlled trials, optimal trial population(s) and outcome(s), and regulatory compliance are all critical. Clinical researchers must consider the possibility of "floor effects" for ingredients present in the diet (3), and of "drop in" for supplements available over the counter.Weaver and Hodges adapted general best practices guidelines for human nutrition randomized controlled trials (4) specifically to plant-based interventions. Both Funk and Schneider and Weaver and Hodges note that while clinical trials are the gold standard for testing efficacy and providing evidence of causality, they should be undertaken only where they address a novel question of substantial public health significance.Funk and Schneider note that clinical trials based on traditional uses may be less likely to succeed where the effect of interest is more likely to respond to a placebo, and that translation of ethnobotanical research may be complicated by cultural differences in symptomatology as well as in other behaviors or even pharmacogenetics.Wright et al. provide a description of the development of a clinical trial-ready botanical product which meets requirements for toxic contaminants, is comparable in chemistry and dosing to the preclinical research and traditional products, minimizes participant burden (critical for recruitment, retention and compliance), and provides a good match to the placebo control.Weaver and Hodges note the importance of compliance with regulatory requirements, including those for data integrity and participant privacy and safety. Transparency must be ensured through pre-study registration of the trial protocol including the statistical analysis plan. A CONSORT (Consolidated Statement on Reporting (Clinical) Trials) checklist provides guidance for reporting herbal interventions (5). Equally essential for transparency, these authors describe the importance of thorough reporting and FAIR (Findable, Accessible, Interoperable, Replicable) data for the advancement of knowledge, as well as for compliance with requirements of funding agencies.Full adoption of the best practices described by authors in this topic will both increase the value of knowledge gained from translational research using chemically complex NP and increase the utility of NP clinical trial results for improving our understanding of NP effects on human health. Adoption of these practices will provide a more solid foundation for building the evidence base for the use of NP for health. *November 25, 2020 through November 24, 2021

2,347 views

4 citations

PERSPECTIVE
18 January 2022
Designing a Clinical Study With Dietary Supplements: It's All in the Details
Z. Elizabeth Floyd, 4 more and Bill J. Gurley

20,724 views

26 citations

REVIEW
8 February 2022
Interpreting Clinical Trials With Omega-3 Supplements in the Context of Ancestry and FADS Genetic Variation

10,839 views

38 citations

Botanical products are frequently sold as dietary supplements and their use by the public is increasing in popularity. However, the scientific evaluation of their medicinal benefits presents unique challenges due to their chemical complexity, inherent variability, and the involvement of multiple active components and biological targets. Translation away from preclinical models, and developing an optimized, reproducible botanical product for use in clinical trials, presents particular challenges for phytotherapeutic agents compared to single chemical entities. Common deficiencies noted in clinical trials of botanical products include limited characterization of the product tested, inadequate placebo control, and lack of rationale for the type of product tested, dose used, outcome measures or even the study population. Our group has focused on Centella asiatica, an Eastern Medicine botanical, due to its reputation for enhancing cognition. Our preclinical studies on a Centella asiatica water extract (CAW) and its bioactive components strongly support its potential as a phytotherapeutic agent for cognitive decline in aging and Alzheimer’s disease through influences on antioxidant response, mitochondrial activity, and synaptic density. Here we describe our robust, scientific approach towards developing a rational phytotherapeutic product based on Centella asiatica for human investigation, addressing multiple factors to optimize its valid clinical evaluation. Specific aspects covered include approaches to identifying an optimal dose range for clinical assessment, design and composition of a dosage form and matching placebo, sourcing appropriate botanical raw material for product manufacture (including the evaluation of active compounds and contaminants), and up-scaling of laboratory extraction methods to available Current Good Manufacturing Practice (cGMP) certified industrial facilities. We also address the process of obtaining regulatory approvals to proceed with clinical trials. Our study highlights the complexity of translational research on botanicals and the importance of identifying active compounds and developing sound analytical and bioanalytical methods for their determination in botanical materials and biological samples. Recent Phase I pharmacokinetic studies of our Centella asiatica product in humans (NCT03929250, NCT03937908) have highlighted additional challenges associated with designing botanical bioavailability studies, including specific dietary considerations that need to be considered.

11,446 views

21 citations

6,391 views

14 citations

Chemometric-Guided Approaches for Profiling and Authenticating Botanical Materials
Botanical supplements with broad traditional and medicinal uses represent an area of growing importance for American health management; 25% of U.S. adults use dietary supplements daily and collectively spent over $9.5 billion in 2019 in herbal and botanical supplements alone. To understand how natural products benefit human health and determine potential safety concerns, careful in vitro, in vivo, and clinical studies are required. However, botanicals are innately complex systems, with complicated compositions that defy many standard analytical approaches and fluctuate based upon a plethora of factors, including genetics, growth conditions, and harvesting/processing procedures. Robust studies rely upon accurate identification of the plant material, and botanicals’ increasing economic and health importance demand reproducible sourcing, as well as assessment of contamination or adulteration. These quality control needs for botanical products remain a significant problem plaguing researchers in academia as well as the supplement industry, thus posing a risk to consumers and possibly rendering clinical data irreproducible and/or irrelevant. Chemometric approaches that analyze the small molecule composition of materials provide a reliable and high-throughput avenue for botanical authentication. This review emphasizes the need for consistent material and provides insight into the roles of various modern chemometric analyses in evaluating and authenticating botanicals, focusing on advanced methodologies, including targeted and untargeted metabolite analysis, as well as the role of multivariate statistical modeling and machine learning in phytochemical characterization. Furthermore, we will discuss how chemometric approaches can be integrated with orthogonal techniques to provide a more robust approach to authentication, and provide directions for future research.

12,961 views

71 citations

BRIEF RESEARCH REPORT
25 November 2021
Dissolution Study on Grape Polyphenol Hard Gelatin Capsule Dietary Supplements
Weiting Lyu, 8 more and Qingli Wu

8,818 views

9 citations